IDEXX Laboratories, Inc. $IDXX Shares Bought by Wealthfront Advisers LLC

Wealthfront Advisers LLC boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,602 shares of the company’s stock after buying an additional 1,687 shares during the quarter. Wealthfront Advisers LLC’s holdings in IDEXX Laboratories were worth $10,452,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of IDXX. D.A. Davidson & CO. lifted its stake in IDEXX Laboratories by 38.7% in the 1st quarter. D.A. Davidson & CO. now owns 2,923 shares of the company’s stock worth $1,642,000 after purchasing an additional 815 shares in the last quarter. Illinois Municipal Retirement Fund raised its holdings in shares of IDEXX Laboratories by 1.8% during the 1st quarter. Illinois Municipal Retirement Fund now owns 6,616 shares of the company’s stock worth $3,717,000 after acquiring an additional 120 shares during the period. Geneos Wealth Management Inc. boosted its position in shares of IDEXX Laboratories by 2,309.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 5,928 shares of the company’s stock valued at $3,331,000 after acquiring an additional 5,682 shares during the last quarter. Sanctuary Advisors LLC boosted its position in shares of IDEXX Laboratories by 12.8% during the 1st quarter. Sanctuary Advisors LLC now owns 14,364 shares of the company’s stock valued at $8,071,000 after acquiring an additional 1,628 shares during the last quarter. Finally, Checchi Capital Advisers LLC grew its stake in shares of IDEXX Laboratories by 22.7% in the 1st quarter. Checchi Capital Advisers LLC now owns 702 shares of the company’s stock valued at $394,000 after buying an additional 130 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $567.44 on Friday. The firm has a market cap of $44.76 billion, a PE ratio of 41.78, a price-to-earnings-growth ratio of 3.15 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52-week low of $513.02 and a 52-week high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The company’s 50 day moving average is $554.49 and its two-hundred day moving average is $599.94.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Stifel Nicolaus reduced their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Citigroup started coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target on the stock. Finally, UBS Group decreased their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.